This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veeva Systems Collaborates With Walgreens to Improve Patient Outcomes
by Zacks Equity Research
VEEV partners with Walgreens to provide better patient outcomes to life sciences companies.
CVS Q3 Estimates Plunge Before Earnings Release: How to Play the Stock
by Urmimala Biswas
CVS Health faces outpatient and supplemental benefits pressure within Health Care Benefits.
WBA Stock Up 16% on New Restructuring Strategy: How to Play the Stock
by Urmimala Biswas
Walgreens Boots is currently going all out to reform its pharmacy model by aggressively liquidating its unprofitable stores and businesses.
Company News for Oct 16, 2024
by Zacks Equity Research
Companies In The Article Are: WOLF, WBA, SCHW, PNC
WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action
by Zacks Equity Research
Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower
by Mark Vickery
While Goldman Sachs (GS) and Citi (C) both impressed on earnings this morning, Walgreens (WBA) looks to bounce back.
Compared to Estimates, Walgreens (WBA) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Walgreens (WBA) give a sense of how the business performed in the quarter ended August 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Walgreens Boots Alliance (WBA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 8.33% and 5.07%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Q3 Earnings Results of U.S. Corporate Giants in Focus
by Zacks Equity Research
Q3 Earnings Results of U.S. Corporate Giants in Focus.
Bank Holiday Ahead of Busy Stock Trading Week
by Mark Vickery
Despite today's day off from econ metrics, we see a pretty busy week ahead.
Unlocking Q4 Potential of Walgreens (WBA): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Walgreens (WBA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended August 2024.
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens Boots Alliance (WBA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $8.88, denoting a +1.83% change from the preceding trading day.
Assessing WBA Before Q4 Earnings: How Should You Play the Stock?
by Moumi Mondal
A challenging retail environment and pharmacy trends are expected to cloud Walgreens' performance in the fourth quarter of fiscal 2024.
CVS Stock Hits 50-Day SMA on Split Rumors: How Should You Play?
by Urmimala Biswas
The market speculates that following the FTC notice, several investors are pushing CVS Health to go for segment breakups.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $8.96, marking a -1.1% move from the previous day.
Walgreens Boots Alliance (WBA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $8.53, indicating a -0.35% shift from the previous trading day.
WBA Stock Dips 5% Post Fed Rate Cut: Should You Sell Walgreens Boots?
by Urmimala Biswas
WBA is currently facing challenges within its U.S. Retail Pharmacy segment due to an unfavorable consumer environment and adverse pharmacy industry trends.
Walgreens Boots Alliance (WBA) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the most recent trading session, Walgreens Boots Alliance (WBA) closed at $9.01, indicating a -0.55% shift from the previous trading day.
Walgreens Boots Alliance (WBA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Walgreens Boots Alliance (WBA) settling at $8.84, representing a +1.14% change from its previous close.
Why the Market Dipped But Walgreens Boots Alliance (WBA) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Walgreens Boots Alliance (WBA) stood at $8.77, denoting a +0.34% change from the preceding trading day.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon are part of the Zacks Industry Outlook article.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) reachead $8.74 at the closing of the latest trading day, reflecting a +1.04% change compared to its last close.
3 Stocks to Avoid From The Volatile Retail Pharmacy Industry
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS, WBA and HLF are likely to be affected by reimbursement challenges that are hurting the overall health of the industry.